Insiders who reported open-market trades in the last 12 months at the companies Alan J. Russell files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Joanne M. Donovan - $4.62M in EWTX purchases and sales in the last 12 months
Badreddin Edris - $3.40M in EWTX purchases and sales in the last 12 months
Kevin Koch - $785K in EWTX purchases and sales in the last 12 months
Behrad Derakhshan - $223K in EWTX purchases and sales in the last 12 months
John R. Moore - $220K in EWTX purchases and sales in the last 12 months
Jonathan C. Fox - $199K in EWTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Alan J. Russell is a corporate insider, tracked as Chief Scientific Officer, Director of Edgewise Therapeutics, Inc. (EWTX). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Alan J. Russell submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Alan J. Russell been buying or selling stock?
Recorded transactions: 0 open-market purchases and 9 open-market sales ($14.47M) across all tracked filings.
Alan J. Russell is Chief Scientific Officer, Director of Edgewise Therapeutics, Inc. (EWTX). 7 SEC Form 4 filings on record going back to 2024, most recently on 17 August 2026. Most recent open-market trade: sold $17K of EWTX on 14 August 2026. Lifetime open-market sales: $14.47M.
Recent transactions
17
The latest 17 SEC Form 4 transactions reported by Alan J. Russell.
InsiderAlpha's records for Alan J. Russell go back to 2024: 7 primary Form 4 filings, an average of 2.3 per year. 9 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
